SPOTLIGHT -
Mr Lavigne is the chief executive officer of the Schizophrenia & Psychosis Action Alliance.
Advocacy Group Applaud Joint FDA Committee Proposed Changes to Clozapine REMS Requirements
Gordon Lavigne, MEd, CEO of the Schizophrenia & Psychosis Action Alliance, talk about the joint FDA committee's vote on clozapine REMS.
Insights From the 2025 APA Annual Meeting
May in Review: Updates on the Psychiatric Treatment Pipeline
DEI Concerns in Psychiatric Organizations
Treatment Comparison: Somnolence/Sedation With Dopamine Partial Agonists vs D2 Receptor Antagonists